Advertisement

Risk factors for aluminum toxicity and its prevention

  • Jack W. Coburn
  • William G. Goodman
Chapter
Part of the Developments in Nephrology book series (DINE, volume 26)

Abstract

This chapter addresses the questions: What are the risk factors for aluminum toxicity? and what can be done to minimize these risks? The clinical syndromes of aluminum toxicity to be considered are: 1) encephalopathy, 2) aluminum-related bone disease (often including some degree of proximal myopathy) and 3) anemia. The relationship between aluminum loading and tissue toxicity has been most carefully evaluated in aluminum-related bone disease, and the other syndromes will be considered only when the risk factors may be different. However, even with bone disease, the definitions of aluminum toxicity have been arbitrary and criteria for its diagnosis have been vague or variable. For the purposes of this chapter, patients with bone biopsies showing significant aluminum staining (>25–30% of trabecular surface) and reduced bone formation rates (either with or without the typical features of osteomalacia) are considered to have aluminum-related bone disease [1]. Patients with minimal or absent aluminum staining and bone formation rates that are normal or high are generally considered not to have aluminum toxicity [1–4].

Keywords

Dialysis Patient Aluminum Hydroxide Aluminum Toxicity Microcytic Anemia Aluminum Level 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Salusky IB, Coburn JW, Brill J, Foley J, Slatopolsky E, Fine RN, Goodman WG, 1988: Bone disease in pediatric patients undergoing dialysis with CAPD or CCPD. Kidney Int 33: 975.PubMedGoogle Scholar
  2. 2.
    Andress DL, Maloney NA, Coburn JW, Endres DB, Sherrard DJ, 1987: Osteomalacia and aplastic bone disease in aluminum-related osteodystrophy. J Clin Endocrinol Metab 65: 11.PubMedGoogle Scholar
  3. 3.
    Andress DL, Hercz G, Kopp JB, Endres DB, Norris KC, Coburn JW, Sherrard DJ, 1987: Bone histomorphometry of renal osteodystrophy in diabetic patients. J Bone Miner Res 2: 525.PubMedGoogle Scholar
  4. 4.
    Turner NW, Ardilia M, Hutchinson T, Prichard S, Barre PE, Beauvais J, Kaye M, 1988: Sporadic aluminum osteomalacia: Identification of patients at risk. Am J Kidney Dis 11: 51.PubMedGoogle Scholar
  5. 5.
    Kovalchik MT, Kaehny WD, Hegg AP, Jackson JT, Alfrey AC, 1978: Aluminum kinetics during hemodialysis. J Lab Clin Med 92: 712.PubMedGoogle Scholar
  6. 6.
    Coburn JW, Norris KC, Sherrard DJ, Bia M, Llach F, Alfrey AC, Slatopolsky E, 1988: Toxic effects of aluminum in end-stage renal failure: A case discussion. Am J Kidney Dis 12: 171.PubMedGoogle Scholar
  7. 7.
    Alfrey AC, LeGendre GR, Kaehny WD, 1976: The dialysis encephalopathy syndrome: Possible aluminum intoxication. N Engl J Med 294: 184.PubMedGoogle Scholar
  8. 8.
    Prior JC, Cameron EC, Knickerbocker WJ, Sweeney VP, Suchowersky O, 1982: Dialysis encephalopathy and osteomalacic bone disease: a case-controlled study. Am J Med 72: 33.PubMedGoogle Scholar
  9. 9.
    Rozas VV, Port FK, and Easterling RE, 1978: An outbreak of dialysis dementia due to aluminum in the dialyaste. J Dialysis 2: 459.Google Scholar
  10. 10.
    Berkseth RO, Shapiro FL, 1980: An epidemic of dialysis encephalopathy and exposure to high aluminum dialysate. In: Controversies in Nephrology. GE Schreiner, and JF Winchester, editors. Georgetown University Press, Washington, DC: pp. 42–51.Google Scholar
  11. 11.
    Davidson AM, Walker GS, Oli H, Lewins AM, 1982: Water supply aluminum concentration, dialysis dementia, and effect of reverse-osmosis water treatment. Lancet 2: 785.Google Scholar
  12. 12.
    Alfrey AC, 1983: Aluminum. Adv Clin Chem 23: 69.PubMedGoogle Scholar
  13. 13.
    Platts MM, Goods GC, Hislop JS, 1977: Composition of the domestic water supply and the incidence of fractures and encephalopathy in patients on home dialysis. Br Med J 2: 657.PubMedGoogle Scholar
  14. 14.
    Parkinson IS, Feest TG, Ward MK, Fawcett RWP, Kerr DNS, 1979: Fracturing dialysis osteodystrophy and dialysis encephalopathy: an epidemiological survey. Lancet 1: 406.PubMedGoogle Scholar
  15. 15.
    Kerr DNS, Ward MK, Arze RS, Ramos JM, Grekas D, Parkinson IS, Ellis HA, Owen JP, Simpson W, Dewar J, Martin AM, McHugh MF, 1986: Aluminum-induced dialysis osteodystrophy: The demise of ‘Newcastle bone disease’. Kidney Int [Suppl 18] 29: S58.Google Scholar
  16. 16.
    Ricanati ES, Ott SM, Klein GL, Alfrey AC, Sherrard DJ, Coburn JW, 1982: Evaluation of bone in dialysis patients exposed to aluminum in dialysate. Kidney Int 21: 176. (Abstract)Google Scholar
  17. 17.
    O’Hare JA, Murnaghan DJ, 1982: Reversal of aluminum-induced hemodialysis anemia by a low-aluminum dialysate. N Engl J Med 306: 654.PubMedGoogle Scholar
  18. 18.
    McGonigle RJ, Parsons V, 1985: Aluminium-induced anaemia in haemodialysis patients. Nephron 39: 1.PubMedGoogle Scholar
  19. 19.
    Short A, Winney RJ, Robson JS, 1980: Reversible microcytic hypochromic anaemia in dialysis patients with aluminum intoxication. Proc EDTA 17: 226.Google Scholar
  20. 20.
    Touam M, Martinez F, Lacour B, Bourdon R, Zingraff J, DiGuilio S, Drueke T, 1983: Aluminum-induced, reversible microcytic anemia in chronic renal failure: Clinical and experimental studies. Clin Nephrol 19: 295.PubMedGoogle Scholar
  21. 21.
    Norris KC, Crooks PW, Nebeker HG, Hercz G, Milliner DS, Gerszi K, Slatopolsky E, Andress DL, Sherrard DJ, Coburn JW, 1985: Clinical and laboratory features of aluminum- related bone disease: differences between sporadic and ’epidemic’ forms of the syndrome. Am J Kidney Dis 6: 342.PubMedGoogle Scholar
  22. 22.
    Shortle WC, Smith KT, 1988: Aluminum-induced calcium deficiency syndrome in declining red spruce. Science 240: 1017.PubMedGoogle Scholar
  23. 23.
    Flendrig JA, Kruis H, Das HA, 1976: Aluminum intoxication: The cause of dialysis dementia. Proc EDTA 13: 355.Google Scholar
  24. 24.
    Shapiro WB, Schilb TP, Waltrous CL, Levy SR, Porush JG, 1983: Aluminum leakage from REDY sorbent cartridge. Kidney Int 23: 536.PubMedGoogle Scholar
  25. 25.
    Branger B, Ramperez P, Marigliano N, Mion H, Shaldon S, Mion C, 1980: Aluminum transfer in bicarbonate dialysis using a sorbent regenerative system: an in vitro study. Proc EDTA 17: 213.Google Scholar
  26. 26.
    Mason JC, Jones NF, Hilton PJ, 1983: Aluminum in haemofiltration solutions. Lancet 1: 763.Google Scholar
  27. 27.
    Cumming AD, Simpson G, Bell D, Cowie J, Winney RJ, 1982: Acute aluminum intoxication in patients on continuous peritoneal dialysis. Lancet 1: 103.PubMedGoogle Scholar
  28. 28.
    Van de Vyver F, Van Waeleghem J-P, De Broe ME, D’Haese P, Heyndricks A, 1982: Water treatment an dialysis dementia. Lancet 1: 1106.Google Scholar
  29. 29.
    Hercz G, Kraut JA, Andress DL, Howard N, Roberts C, Shinaberger JH, Sherrard DJ, Coburn JW, 1986: Use of calcium carbonate as a phosphate binder in dialysis patients. Miner Electrolyte Metab 12: 314.PubMedGoogle Scholar
  30. 30.
    Salusky IB, Coburn JW, Foley J, Nelson P, Fine RN, 1986: Effects of oral calcium carbonate on control of serum phosphorus and changes in plasma aluminum levels after discontinuation of aluminum-containing gels in children receiving dialysis. J Pediatrics 108: 767.Google Scholar
  31. 31.
    Kaehny WD, Alfrey AC, Holman RE, Shorr WJ, 1977: Aluminum transfer during hemodialysis. Kidney Int 12: 361.PubMedGoogle Scholar
  32. 32.
    Trapp GA, 1983: Plasma aluminum is bound to transferrin. Life Sciences 33: 311.PubMedGoogle Scholar
  33. 33.
    Standards for Hemodialysis Systems, editors. American Association for the Advancement of Medical Instrumentation, 11. 1980.Google Scholar
  34. 34.
    Hercz G, Andress DL, Norris KC, Shinaberger JH, Slatopolsky E, Sherrard DJ, Coburn JW, 1987: Improved bone formation after replacing aluminum gels with calcium carbonate in dialysis patients with aplastic bone disease. Trans Assn Amer Physicians 100: 139.Google Scholar
  35. 35.
    Vargas JH, Klein GL, Ament ME, Ott SM, Sherrard DJ, Horst RL, Berquist WE, Alfrey AC, Slatopolsky E, Coburn JW, 1988: Metabolic bone disease associated with total parenteral nutrition: Course after reducing aluminum content in parenteral solutions. Am J Clin Nutr 480: 1070.Google Scholar
  36. 36.
    Klein GL, Ott SM, Alfrey AC, Sherrard DJ, Hazlet TK, Miller NL, Maloney NA, Berquist WE, Ament ME, Coburn JW, 1982: Aluminum as a factor in the bone disease of long-term parenteral nutrition. Trans Assoc Am Physicians 95: 155.PubMedGoogle Scholar
  37. 37.
    Milliner DS, Shinaberger JH, Shuman P, Coburn JW, 1985: Inadvertent aluminum administration during plasma exchange due to aluminum contamination of albumin-replacement solutions. N Engl J Med 312: 165.PubMedGoogle Scholar
  38. 38.
    Mäher ER, Brown EA, Curtis JR, Phillips ME, Sampson B, 1986: Accumulation of aluminum in chronic renal failure due to administration of albumin replacement solutions. Br Med J [Clin Res] 292: 306.Google Scholar
  39. 39.
    Sedman AB, Klein GL, Merritt RJ, Miller NL, Weber KO, Gill WL, Anand H, Alfrey AC, 1985: Evidence of aluminum loading in infants receiving intravenous therapy. N Engl J Med 312: 1337.PubMedGoogle Scholar
  40. 40.
    Nathan E, Pederson SE, 1980: Dialysis encephalopathy in a non-dialysed uremic boy treated with aluminum hydroxide orally. Acta Paediatr Scand 69: 793.PubMedGoogle Scholar
  41. 41.
    Mehta RP, 1979: Encephalopathy in chronic renal failure appearing before the start of dialysis. Canad Med Assoc J 120: 1112.PubMedGoogle Scholar
  42. 42.
    Griswold WR, Reznik V, Mendoza SA, Trauner D, Alfrey AC, 1983: Accumulation of aluminum in a nondialyzed uremic child receiving aluminum hydroxide. Pediatrics 71: 56.PubMedGoogle Scholar
  43. 43.
    Felsenfeld AJ, Gutman RA, Llach F, Harrelson JM, 1982: Osteomalacia in chronic renal failure: a syndrome previously reported only with maintenance dialysis: Am J Nephrol 2: 147.PubMedGoogle Scholar
  44. 44.
    Andreoli SP, Bergstein JM, Sherrard DJ, 1984: Aluminum intoxication from aluminum- containing phosphate binders in children with azotemia not undergoing dialysis. N Engl J Med 310: 1079.PubMedGoogle Scholar
  45. 45.
    Kaye M, 1983: Oral aluminum toxicity in a non-dialyzed patient with renal failure. Clin Nephrol 20: 208.PubMedGoogle Scholar
  46. 46.
    Salusky IB, Coburn JW, Paunier L, Sherrard DJ, Fine RN, 1984: Role of aluminum hydroxide in raising serum aluminum levels in children undergoing continuous ambulatory peritoneal dialysis. J Pediatr 105: 717.PubMedGoogle Scholar
  47. 47.
    Heaf JG, Nielsen LP, 1984: Serum aluminium in haemodialysis patients: relation to osteodystrophy, encephalopathy and aluminium hydroxide consumption. Miner Electrolyte Metab 10: 345.PubMedGoogle Scholar
  48. 48.
    van der Meulen J, Bezemer PD, Lips P, Os PL, 1984: Individual differences in gastrointestinal absorption of aluminum. N Engl J Med 311: 1322.PubMedGoogle Scholar
  49. 49.
    Slatopolsky E, Weerts C, Lopez-Hilker S, Norwood K, Zink M, Windus M, Delmez J, 1986: Calcium carbonate is an effective phosphate binder in patients with chronic renal failure undergoing dialysis. N Engl J Med 315: 157.PubMedGoogle Scholar
  50. 50.
    Alfrey AC, 1984: Aluminum intoxication. N Engl J Med 310: 1113.PubMedGoogle Scholar
  51. 51.
    Winney RJ, Cowie JF, Robson JS, 1986: The role of plasma aluminum in the detection and prevention of aluminum toxicity. Kidney Int [Suppl 18] 29: S91.Google Scholar
  52. 52.
    Sedman AB, Miller NL, Warady BA, Lum GM, Alfrey AC, 1984: Aluminum loading in children with chronic renal failure. Kidney Int 26: 201.PubMedGoogle Scholar
  53. 53.
    Heaf JG, Podenphant J, Andersen JR, 1986: Bone aluminum deposition in maintenance dialysis patients treated with aluminum-free dialysate: role of aluminium hydroxide consumption. Nephron 42: 210.PubMedGoogle Scholar
  54. 54.
    Hodsman AB, Sherrard DJ, Alfrey AC, Ott SM, Brickman AS, Miller NL, Maloney NA, Coburn JW, 1982: Bone aluminum and histomorphometric features of renal osteodystrophy. J Clin Endocrinol Metab 54: 539.PubMedGoogle Scholar
  55. 55.
    Llach F, Felsenfled AJ, Coleman MD, Keveney Jr JJ, Pederson JA, Medlock TR, 1986: The natural course of dialysis osteomalacia. Kidney Int 29: S74.Google Scholar
  56. 56.
    Larson EA, Ash SR, White JL, Hem SL, 1966: Phosphate binding gels: Balancing phosphate absorption and aluminum toxicity. Kidney Int 29: 1131.Google Scholar
  57. 57.
    Kaehny WD, Hegg P, Alfrey AC, 1977: Gastrointestinal absorption of aluminum from aluminum-containing antacids. N Engl J Med 296: 1389.PubMedGoogle Scholar
  58. 58.
    Robertson JA, Salusky IB, Norris KC, Coburn JW, 1987: Aluminum absorption in man: comparison of sucralfate and aluminum hydroxide. Kidney Int 31: 214. (Abstract)Google Scholar
  59. 59.
    Slanina P, Freeh W, Ekstrom L, Loof L, Slorach S, Cedergren A, 1986: Dietary citric acid enhances absorption of aluminum in antacids. Clin Chem 32: 539.PubMedGoogle Scholar
  60. 60.
    Weberg R, Berstad A, 1986: Gastrointestinal absorption of aluminum from single doses of aluminum containing antacids in man. Eur J Clin Invest 16: 428.PubMedGoogle Scholar
  61. 61.
    Martin RB, 1986: The chemistry of aluminum as related to biology and medicine. Clin Chem 32: 1797.PubMedGoogle Scholar
  62. 62.
    Froment DH, Molitoris BA, Alfrey AC, 1989: Mechanism of enhanced gastrointestinal (GI) absorption (ABS) of aluminum (AL). Kidney Int 35: (Abstract)Google Scholar
  63. 63.
    Bakir AA, Hryhorczuk DD, Berman E, Dunea G, 1986: Acute fatal hyperaluminemic encephalopathy in undialyzed and recently dialyzed uremic patients. Trans Am Soc Artif Intern Organs 32: 171.Google Scholar
  64. 64.
    Kirschbaum BB, Schoolwerth AC, 1989: Acute aluminum toxicity associated with oral citrate and aluminum-containing antacids. Am J Med Sci 279: 9.Google Scholar
  65. 65.
    Mischel MG, Salusky IB, Goodman WG, Coburn JW, 1989: Calcium citrate markedly augments aluminum absorption in man. Kidney Int 35: 400. (Abstract)Google Scholar
  66. 66.
    Anthony J, Fadl S, Mason C, Davison A, Berry J, 1986: Absorption, deposition and distribution of dietary aluminum in immature rats: effects of dietary vitamin D3 and food-borne chelating agent. J Environ Sci Health B21: 191.Google Scholar
  67. 67.
    Mayor GH, Keiser J A, Makdani D, Ku PK, 1977: Aluminum absorption and distribution: effect of parathyroid hormone. Science 197: 1187.PubMedGoogle Scholar
  68. 68.
    Stivelman J, Hakim R, Schulman G, et al., 1985: Exacerbation of possible dialysis encephalopathy with deferoxamine. Am J Kidney Dis 6: A21. (Abstract)Google Scholar
  69. 69.
    Van Der Voet GB, de Wolff FA, 1985: Intestinal absorption of aluminum in rats. Arch Toxicol Suppl 8: 316.Google Scholar
  70. 70.
    Coburn JW, Roberston JA, Norris KC, Salusky IB, Goodman WG, 1989: Effect of ranitidine on aluminum absorption in man. Kidney Int 35: 398. (Abstract)Google Scholar
  71. 71.
    Dreuke T, Lacour B, Touam M, Basile C, Bourdon R, 1985: Oral aluminum administration to uremic, hyperparathyroid or vitamin D-supplemented rats. Nephron 39: 10.Google Scholar
  72. 72.
    Demontis R, Leflon A, Fournier A, Tahiri Y, Herve M, Moriniere Ph, Abdull-Massih Z, Atik H, Belbrik S, Renaud H, Plaquet R, 1986: l’(OH) vitamin D3 increases plasma aluminum in hemodialised patients taking Al(OH)3. Clin Nephrol 29: 146.Google Scholar
  73. 73.
    Ittle TH, Sieberth HC, 1988: Vitamin D status and intestinal absorption of aluminum in rats with normal and reduced renal function. In: Vitamin D: Molecular, Cellular and Clinical Endocrinology. Norman AW, Schaefer L, Grigoleit HG, and v Herrath D, Editors. Walter de Gruyter, Berlin: pp. 439–440.Google Scholar
  74. 74.
    Alfrey AC, 1980: Aluminum metabolism in uremia. Neurotoxicol 1: 43.Google Scholar
  75. 75.
    Ittel TH, Buddington B, Miller NL, Alfrey AC, 1987: Enhanced gastrointestinal absorption of aluminum in uremic rats. Kidney Int 32: 821.PubMedGoogle Scholar
  76. 76.
    Freundlich M, Zilleruelo G, Abitbol C, Strauss J, Faugere MC, Malluche HH, 1985: Infant formula as a cause of aluminium toxicity in neonatal uraemia. Lancet 2: 527.PubMedGoogle Scholar
  77. 77.
    Trapp GA, Cannon JB, 1981: Aluminum pots as a source of dietary aluminum. N Engl J Med 304: 172.PubMedGoogle Scholar
  78. 78.
    Cannata JB, Briggs JD, Junor BJR, Fell GS, 1982: Aluminum hydroxide intake: real risk of aluminum toxicity. Br Med J 284: 776.Google Scholar
  79. 79.
    Rotellar C, Winchester JF, Melhorn NL, Rakowski TA, Mackow RC, Borgiasz S, Black J, Aggy WP, Schreiner GE, Rotellar E, 1989: Iron and aluminum status in dialysis patients. Submitted for publication.Google Scholar
  80. 80.
    Rovelli E, Luciani L, Pagani C, Albonico C, Colleoni N, D’Amico G, 1988: Correlation between serum aluminum concentration and signs of encephalopathy in a large population of.patients dialyzed with aluminum-free fluids. Clin Nephrol 29: 298.Google Scholar
  81. 81.
    Altmann P, Marsh F, Plowman D, Cunningham J, 1988: Aluminum chelation therapy in dialysis patients: evidence for inhibition of haemoglobin synthesis by low levels of aluminum. Lancet 1: 1012.PubMedGoogle Scholar
  82. 82.
    de la Serna F-J, Gilsanz F, Ruilope L-M, 1988: Improvement in the erythropoiesis of chronic haemodialysis patients with desferoxamine. Lancet 1: 1009.PubMedGoogle Scholar
  83. 83.
    Ellis HA, 1982: Aluminum and osteomalacia after parathyroidectomy. Ann Intern Med 96: 533.PubMedGoogle Scholar
  84. 84.
    Cournot-Witmer G, Zingraff J, Plachot JJ, Escaig F, Lefevre R, Boumati P, Bourdeau A, Garabedian M, Galle P, Bourdon R, Dreuke T, Balsan S, 1981: Aluminum localization in bone from hemodialyzed patients: Relationship to matrix mineralization. Kidney Int 20: 375.PubMedGoogle Scholar
  85. 85.
    Felsenfeld AJ, Harrelson JM, Gutman RA, Wells SA, Drezner MK, 1982: Osteomalacia after parathyroidectomy in patients with uremia. Ann Intern Med 960: 34.Google Scholar
  86. 86.
    Teitelbaum SL, Bergfeld MA, Freitag J, Hruska KA, Slatopolsky E, 1980: Do parathyroid hormone and 1, 25-dihyroxyvitamin D modulate bone formation in uremia. J Clin Endocrinol Metab 51: 247.PubMedGoogle Scholar
  87. 87.
    Andress DL, Ott SM, Maloney NA, Sherrard DJ, 1985: Effect of parathyroidectomy on bone aluminum accumulation in chronic renal failure. N Engl J Med 312: 468.PubMedGoogle Scholar
  88. 88.
    Hodsman AB, Sherrard DJ, Wong EGC, Brickman AS, Lee DBN, Alfrey AC, Singer FR, Norman AW, Coburn JW, 1981: Vitamin D resistant osteomalacia in hemodialysis patients lacking secondary hyperparathyroidism. Ann Intern Med 94: 629.PubMedGoogle Scholar
  89. 89.
    Goodman WG, 1987: Thyroparathyroidectomy modifies the skeletal response to aluminum loading in the rat. Kidney Int 31: 923.PubMedGoogle Scholar
  90. 90.
    Alfrey AC, Sedman A, Chan YL, 1985: The compartmentalization and metabolism of aluminum in uremic rats. J Lab Clin Med 105: 227.PubMedGoogle Scholar
  91. 91.
    Andress DL, Kopp JB, Maloney NA, Coburn JW, Sherrard DJ, 1987: Early deposition of aluminum in bone in diabetic patients on hemodialysis. N Engl J Med 316: 292.PubMedGoogle Scholar
  92. 92.
    Heath HH, Lambert PW, Service FJ, Arnaud SB, 1979: J Clin Endocrinol Metab 49: 462.PubMedGoogle Scholar
  93. 93.
    Avram MM, 1980: Contrib Nephrol 20: 4.PubMedGoogle Scholar
  94. 94.
    Hahn TJ, Westbrook SL, Halstead LR, 1984: Cortisol modulation of osteoblast metabolic activity in cultured neonatal rat bone. Endocrinology 114: 1864.PubMedGoogle Scholar
  95. 95.
    Slovik DM, Neer RM, Ohman JL, Lowell FC, Clark MB, Segre GV, Potts JT Jr, 1980: Parathyroid hormone and 25-hydroxyvitamin D levels in glucocorticoid-treated patients. Clin Endocrinol (Oxf) 12: 243.Google Scholar
  96. 96.
    Kanis JA, Earnshaw M, Heynen G, Ledingham JGG, Oliver DO, Russell RGG, Woods CG, Franchmont P, Gaspar S, 1977: Changes in histological and biochemical indexes of bone turnover after bilateral nephrectomy in patients on hemodialysis: Evidence for a possible role of endogenous calcitonin. N Engl J Med 296: 1073.PubMedGoogle Scholar
  97. 97.
    de Verne joui MC, Marcheis S, London G, Morieux C, 1988: Age at onset of dialysis and renal osteodystrophy. J Bone Miner Res [Suppl 1] 3: S94.Google Scholar
  98. 98.
    Gokal R, Fryer R, McHugh M, Ward MK, Kerr DNS, 1980: Calcium and phosphate control in patients on continuous ambulatory peritoneal dialysis. In: Continuous Ambulatory Peritoneal Dialysis. M. Legrain, Editor. Excerpta Medica, Amsterdam, pp. 283–291.Google Scholar
  99. 99.
    Bregman H, Winchester JF, Knepshield JH, Gelfand MC, Manz HJ, Schreiner GE, 1985: Iron-overload-associated myopathy in patients on maintenance haemodialysis: A histocompatability-linked disorder. Lancet 2: 882.Google Scholar
  100. 100.
    Gomez E, Ortega F, Morales JM, et al., 1981: Serum ferritin and HLA antigens in patients on maintenance haemodialysis. Lancet 1: 836.PubMedGoogle Scholar
  101. 101.
    Lipinski M, Hors J, Saleun J, et al., 1978: Idiopathic haemochromatosis: Linkage with HLA. Tissue Antigens 11: 471.PubMedGoogle Scholar
  102. 102.
    Simon M, Bourel M, Genetet B, et al., 1977: Idiopathic hemochromatosis: demonstration of recessive transmission and early detection by family HLA typing. N Engl J Med 297: 1017.PubMedGoogle Scholar
  103. 103.
    Sherrard DJ, Walker JV, Boykin JL, 1988: Precipitation of dialysis dementia by deferoxamine treatment of aluminum-related bone disease. Am J Kidney Dis 12: 126.PubMedGoogle Scholar
  104. 104.
    McClure J, Fazzalari NL, Fassett RG, Pugsley DJ, 1983: Bone histoquantitative findings and histochemical staining reactions for aluminium in chronic renal failure patients treated with haemodialysis fluids containing high and low concentrations of aluminium. J Clin Pathol 36: 1281.PubMedGoogle Scholar
  105. 105.
    Ackrill P, Day JP, 1984: Therapy of aluminum overload. II. Contrib Nephrol 38: 78.PubMedGoogle Scholar
  106. 106.
    Swartz RD, 1985: Deferoxamine and aluminum removal. Am J Kidney Dis 6: 358.PubMedGoogle Scholar
  107. 107.
    Ott SM, 1983: Aluminum-related osteomalacia. Int J Artif Organs 6: 173.PubMedGoogle Scholar
  108. 108.
    Luda E, Canavese C, Roca G, 1984: The EEG in progressive dialysis encephalopathy. Ital J Neurol Sei 5: 375.Google Scholar
  109. 109.
    Fournier A, Moriniere PH, Sebert JL, Dkhissi H, Atik A, Leflon P, Renaud H, Guéris J, Gregoire I, Idrissi A, Garabedian M, 1986: Calcium carbonate, an aluminum-free agent for control of hyperphosphatemia, hypocalcemia and hyperparathyroidism in uremia. Kidney Int 29: S115.Google Scholar
  110. 110.
    Moriniere PH, Roussel A, Tahiri Y, Forniere A, 1982: Substitution of aluminum hydroxide by high doses of calcium carbonate in patients on chronic hemodualysis: Disappearance of hyperaluminemia and equal control of hyperparathyroidism. Proc Eur Dial Transplant Assoc 19: 784.Google Scholar
  111. 111.
    Mactier AA, Van Stone J, Cox A, Van Stone M, Twardowski Z, 1987: Calcium carbonate is an effective phosphate binder when dialysate calcium concentration is adjusted to control hypercalcemia. Clin Nephrol 28: 222.PubMedGoogle Scholar
  112. 112.
    Schneider H, Kulbe KD, Weber H, Stricher E, 1983: High-effective aluminum free phosphate binder. In vitro and in vivo studies. Proc EDTA 20: 725.Google Scholar
  113. 113.
    O’Donovan R, Baldwin D, Hammer M, et al., 1986: Substitution of aluminum salts by magnesium salts in control of dialysis hyperphosphatemia. Lancet 1: 880.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1990

Authors and Affiliations

  • Jack W. Coburn
  • William G. Goodman

There are no affiliations available

Personalised recommendations